Cargando…

First person – Mugagga Kalyesubula and Ramgopal Mopuri

First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Mugagga Kalyesubula and Ramgopal Mopuri are co-first authors on ‘High-dose vitamin B1 thera...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988767/
http://dx.doi.org/10.1242/dmm.048941
_version_ 1783668843467505664
collection PubMed
description First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Mugagga Kalyesubula and Ramgopal Mopuri are co-first authors on ‘High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition’, published in DMM. Mugagga is a PhD student in the lab of Dr Hay Dvir at the Volcani Center – Agricultural Research Organization (ARO), Rishon LeZion, Israel and The Hebrew University of Jerusalem, Rehovot, Israel, investigating therapy development for chronic metabolic diseases such as non-alcoholic fatty liver disease. Ramgopal is a postdoctoral researcher in the lab of Dr Hay Dvir at the Volcani Center – ARO in Rishon LeZion, Israel, developing therapeutic approaches for the management of fatty liver diseases.
format Online
Article
Text
id pubmed-7988767
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Company of Biologists Ltd
record_format MEDLINE/PubMed
spelling pubmed-79887672021-03-25 First person – Mugagga Kalyesubula and Ramgopal Mopuri Dis Model Mech First Person First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Mugagga Kalyesubula and Ramgopal Mopuri are co-first authors on ‘High-dose vitamin B1 therapy prevents the development of experimental fatty liver driven by overnutrition’, published in DMM. Mugagga is a PhD student in the lab of Dr Hay Dvir at the Volcani Center – Agricultural Research Organization (ARO), Rishon LeZion, Israel and The Hebrew University of Jerusalem, Rehovot, Israel, investigating therapy development for chronic metabolic diseases such as non-alcoholic fatty liver disease. Ramgopal is a postdoctoral researcher in the lab of Dr Hay Dvir at the Volcani Center – ARO in Rishon LeZion, Israel, developing therapeutic approaches for the management of fatty liver diseases. The Company of Biologists Ltd 2021-03-18 /pmc/articles/PMC7988767/ http://dx.doi.org/10.1242/dmm.048941 Text en © 2021. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/4.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
spellingShingle First Person
First person – Mugagga Kalyesubula and Ramgopal Mopuri
title First person – Mugagga Kalyesubula and Ramgopal Mopuri
title_full First person – Mugagga Kalyesubula and Ramgopal Mopuri
title_fullStr First person – Mugagga Kalyesubula and Ramgopal Mopuri
title_full_unstemmed First person – Mugagga Kalyesubula and Ramgopal Mopuri
title_short First person – Mugagga Kalyesubula and Ramgopal Mopuri
title_sort first person – mugagga kalyesubula and ramgopal mopuri
topic First Person
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7988767/
http://dx.doi.org/10.1242/dmm.048941